FDA
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Post Release of Setmelanotide Data
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothal
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalam
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $140 at Canaccord
-
-
-
-
-
-
-
Rhythm Pharmaceuticals reports $57M Q4 revenue, 50% annual growth
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
-
326,547 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

